Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
Last trade$12.30
Day change-$0.24 (-1.91%)
Day range$12.22 – $12.71
Volume29,342
Market cap$140M
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$140.23M
Price / earnings
—
Price / book
0.78×
Price / sales
0.47×
EV / sales
0.27×
EV / EBITDA
-3.72×
Profitability
Earnings per share
-$3.65
Return on assets
-17.04%
Return on equity
-22.66%
Dividend yield
0.12%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.82×
Quick ratio
4.32×
Cash ratio
1.39×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$3.87M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MED, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$72.05M
$76.38M
$76.04M
$75.1M
$89.41M
$105.56M
$115.73M
$119M
Cost of revenue
$22.01M
$22.99M
$24.29M
$22.96M
$27.25M
$28.91M
$31.48M
$30.78M
Gross profit
$50.04M
$53.4M
$51.76M
$52.14M
$62.16M
$76.64M
$84.25M
$88.22M
Selling, general and administrative
$69.4M
$57.72M
$55.05M
$59.94M
$66.24M
$77.71M
$85.51M
$87.51M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$69.4M
$57.72M
$55.05M
$59.94M
$66.24M
$77.71M
$85.51M
$87.51M
Operating income
-$19.36M
-$4.33M
-$3.3M
-$7.8M
-$4.08M
-$1.07M
-$1.26M
$709K
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$17.84M
-$2.99M
-$1.94M
-$6.38M
-$2.66M
$2.88M
$526K
$1.28M
Income taxes
-$324K
$109K
$181K
$11.74M
-$396K
$395K
$1.3M
$474K
Net income
-$17.51M
-$3.1M
-$2.12M
-$18.12M
-$2.26M
$2.48M
-$772K
$801K
Net income attributable to common shareholders
-$17.51M
-$3.1M
-$2.12M
-$18.12M
-$2.26M
$2.48M
-$772K
$801K
EBITDA
-$17M
-$881K
$188K
-$4.34M
-$629K
$2.98M
$2.02M
$3.89M
Basic earnings per share
-$1.57
-$0.28
-$0.19
-$1.65
-$0.21
$0.23
-$0.07
$0.07
Diluted earnings per share
-$1.57
-$0.28
-$0.19
-$1.66
-$0.21
$0.22
-$0.07
$0.07
Recent news
Company coverage with links to the original publishers.
Medifast (MED) launched its Metabolic Health Institute, leveraging 45 years of scientific expertise to transition from a weight-loss company to a comprehensive metabolic health platform. The company identified a $12 trillion existing metabolic health market with $16 trillion in untapped prevention opportunities. MED's Trilivy system now includes Refine and Renew phases to support metabolic flexibility and long-term health optimization.
Medifast reported Q3 2026 revenue of $72 million with a strategic pivot toward metabolic health products. The company reduced its active coach count to 10.2 thousand but increased average revenue per coach by 54% through compensation restructuring. Cost-cutting initiatives and a debt-free balance sheet with $172.5 million in cash provide runway for growth, with management targeting Q4 2026 profitability.
Medifast (MED) reported Q3 2026 results with a narrower-than-expected loss of 19 cents per share, beating consensus estimates. While revenues declined 19.4% year-over-year to $72 million, the company demonstrated improved coach productivity (up 54.1%) and raised its full-year 2026 revenue guidance to $280-$300 million with adjusted EBITDA expectations of $10-$14 million. However, active earning coaches dropped 47.7% due to client acquisition challenges amid GLP-1 medication competition.
Medifast (MED) is set to report Q3 fiscal 2026 results on October 26, with consensus expectations for $68 million in revenues (down 23.9% YoY) and a loss of 40 cents per share. The company faces headwinds from growing GLP-1 medication adoption, declining active coach numbers, and reduced client acquisition, though cost-saving initiatives and improved client retention may provide some support.